ERBB2 and breast cancer: BROCADE3 is a randomized, double-blind, phase III study that involved 509 patients (337 patients in the veliparib group and 172 patients in the control group) with BRCA1/2 germline-mutated, HER2-negative advanced BC who had received up to two previous lines of chemotherapy for metastatic disease [72].